Join Here   |   Log In

VMAT2 gene: The God Gene and Neurotransmitters

Key takeaways:
~ VMAT2 is nicknamed the “God gene” due to research studies linking it to spirituality.
~ VMAT2 packages up and releases neurotransmitters from neurons, regulating and facilitating neuronal transmission.
~ Genetic variants in VMAT2 alter the risk of alcohol dependence, Parkinson’s, and PTSD.

Members will see their genotype report below and the solutions in the Lifehacks section. Consider joining today

What is the “God” (VMAT2) gene?

Humans have long sought to integrate spirituality and science – wondering how consciousness, thought, feelings, self-transcendence, and spirituality are created in the brain. Genetics researchers have tried to answer these questions over the past few decades, and their search for a genetic basis for spirituality is intriguing.

VMAT2 is a neurotransmitter transporter encoded by the SLC18A2 (solute carrier family 18 member A2) gene.

The God Gene:
VMAT2 has been dubbed the “God gene” due to its reported association with spirituality.[ref] In a 2004 book by Dean Hammer, the VMAT2 gene was hypothesized to be the hereditary or genetic influence on spirituality. The book, called The God Gene: How Faith is Hardwired into our Genes, laid out the idea that spirituality is heritable and, at least partly, due to the VMAT2 gene.

The author suggests that positive selection for feel-good genes creates optimism for living even though death is inevitable.[ref]

What does the VMAT2 gene do?

VMAT2 (SLC18A2 gene) is a monoamine transport gene. It packages monoamine neurotransmitters from the cytosol inside of the neuron into vesicles to be released into the synapse.

Monoamine neurotransmitters include:

  • dopamine
  • serotonin
  • adrenaline
  • noradrenaline
  • histamine
  • melatonin

These are the neurotransmitters important in thinking, behavior, physical movement, pain, emotion, wakefulness, and circulation.[ref][ref]

Learn more about neurotransmitters: dopamine receptors, dopamine synthesis genes, serotonin genes, histamine genes, and COMT.

VMAT2 is important for transporting dopamine, serotonin, and other neurotransmitters into vesicles that are then released in the synapses of the neurons. In the cytosol of the neuronal cell, VMAT2 facilitates the packaging of the monoamines into secretory vesicles. These vesicles then move to the cell membrane to release their neurotransmitter payload into the synapse to send a signal to the next neuron.[ref]

This packaging up of the monoamine neurotransmitters is essential because monoamines are prone to oxidation in the cell. Thus, VMAT2 protects cells from oxidative stress from oxidized monoamines.[ref]

VMAT2 packages dopamine into vesicles before release into the synapse. CC image. PMC7372188

With its role in protecting neurons from oxidative stress, VMAT2 prevents damage to dopaminergic neurons. Parkinson’s results from damage to the dopaminergic neurons in the brain, and type 2 diabetes can result from dopamine damage in the pancreas. Newly developed VMAT-2 inhibitors have a possible side effect of causing Parkinson’s disease.[ref]

Research studies on VMAT-2:

For more than three decades, researchers have probed the functions of VMAT2. Here is a quick overview of recent research:

Parkinson’s:
Faulty dopaminergic transmission is at the root of Parkinson’s. Increased VMAT2 is protective against Parkinson’s disease and also protects against toxicants that can cause Parkinson’s.[ref]

VMAT2 essential for dopamine, serotonin:
Animal studies show that conditionally reducing VMAT2 expression causes a whole-brain decrease in monoamine neurotransmitters.[ref]

Protective against meth:
Increased levels of VMAT2 can protect the brain from damage from methamphetamine.[ref]

Protective against anxiety/depression:
Animal studies also showed that increased VMAT2 is protective against anxiety and depression. Additionally, increased VMTA2 enhances locomotion.[ref]

Protective against diabetes:
Another place VMAT2 is essential is in the beta-cells of the pancreas. Dopamine modulates the release of insulin, and VMAT2 is important here in the packaging up of dopamine. Thus, VMAT2 protects against oxidative stress in beta cells by controlling dopamine release.[ref]

 


VMAT2 Genotype Report

Members: Log in to see your data below.
Not a member? Join here.


Access this content:

An active subscription is required to access this content.

Join as a member



Lifehacks: Altering VMAT2 Levels

VMAT2 inhibitors:

Inhibiting VMAT2 too much can cause Parkinson’s-like symptoms due to its effect on dopamine. The positive side of VMAT2 inhibitors is that they theoretically may help with addiction treatment for cocaine or meth.

Access this content:

An active subscription is required to access this content.

Join as a member



Related Articles and Topics:

Serotonin 2A receptor: Psychedelic response and Alzheimer’s disease

Psychopaths: Born not made?


References:

Bharadwaj, Rahul A., et al. “Genetic Risk Mechanisms of Posttraumatic Stress Disorder in the Human Brain.” Journal of Neuroscience Research, vol. 96, no. 1, Jan. 2018, pp. 21–30. PubMed, https://doi.org/10.1002/jnr.23957.
Blum, Kenneth, et al. “Genospirituality: Our Beliefs, Our Genomes, and Addictions.” Journal of Addiction Research & Therapy, vol. 5, no. 4, Oct. 2013, p. 162. PubMed Central, https://doi.org/10.4172/2155-6105.1000162.
Brighina, Laura, et al. “Analysis of Vesicular Monoamine Transporter 2 Polymorphisms in Parkinson’s Disease.” Neurobiology of Aging, vol. 34, no. 6, June 2013, p. 1712.e9-1712.e13. PubMed Central, https://doi.org/10.1016/j.neurobiolaging.2012.12.020.
Fehr, Christoph, et al. “Association of VMAT2 Gene Polymorphisms with Alcohol Dependence.” Journal of Neural Transmission (Vienna, Austria: 1996), vol. 120, no. 8, Aug. 2013, pp. 1161–69. PubMed, https://doi.org/10.1007/s00702-013-0996-y.
Isingrini, Elsa, et al. “Selective Genetic Disruption of Dopaminergic, Serotonergic and Noradrenergic Neurotransmission: Insights into Motor, Emotional and Addictive Behaviour.” Journal of Psychiatry & Neuroscience : JPN, vol. 41, no. 3, May 2016, pp. 169–81. PubMed Central, https://doi.org/10.1503/jpn.150028.
Kong, Yanyan, et al. “Elucidating the Relationship Between Diabetes Mellitus and Parkinson’s Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2.” Frontiers in Neuroscience, vol. 14, July 2020, p. 682. PubMed Central, https://doi.org/10.3389/fnins.2020.00682.
König, Niclas, et al. “Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse.” Frontiers in Behavioral Neuroscience, vol. 14, Nov. 2020, p. 578443. PubMed Central, https://doi.org/10.3389/fnbeh.2020.578443.
Lohr, Kelly M., Kristen A. Stout, et al. “Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.” ACS Chemical Neuroscience, vol. 6, no. 5, May 2015, pp. 790–99. PubMed Central, https://doi.org/10.1021/acschemneuro.5b00010.
Lohr, Kelly M., Alison I. Bernstein, et al. “Increased Vesicular Monoamine Transporter Enhances Dopamine Release and Opposes Parkinson Disease-Related Neurodegeneration in Vivo.” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 27, July 2014, pp. 9977–82. PubMed Central, https://doi.org/10.1073/pnas.1402134111.
MD, Karley Y. Little, and Anish V. Sharda MPH MD. The Vesicular Monoamine Transporter | Psychiatric Times. 3 Feb. 2026, https://www.psychiatrictimes.com/view/vesicular-monoamine-transporter.
Padmakumar, Manisha, et al. “A Novel Missense Variant in SLC18A2 Causes Recessive Brain Monoamine Vesicular Transport Disease and Absent Serotonin in Platelets.” JIMD Reports, vol. 47, no. 1, May 2019, pp. 9–16. DOI.org (Crossref), https://doi.org/10.1002/jmd2.12030.
Rothenberg, Dylan O’Neill, and Lingyun Zhang. “Mechanisms Underlying the Anti-Depressive Effects of Regular Tea Consumption.” Nutrients, vol. 11, no. 6, June 2019, p. 1361. PubMed Central, https://doi.org/10.3390/nu11061361.
Sakano, Daisuke, et al. “VMAT2 Safeguards β-Cells Against Dopamine Cytotoxicity Under High-Fat Diet–Induced Stress.” Diabetes, vol. 69, no. 11, Nov. 2020, pp. 2377–91. PubMed Central, https://doi.org/10.2337/db20-0207.
Simons, Claudia J. P., and Ruud van Winkel. “Intermediate Phenotype Analysis of Patients, Unaffected Siblings, and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition.” Schizophrenia Bulletin, vol. 39, no. 4, July 2013, pp. 848–56. PubMed Central, https://doi.org/10.1093/schbul/sbs067.
Solovieff, Nadia, et al. “Genetic Association Analysis of 300 Genes Identifies a Risk Haplotype in SLC18A2 for Post-Traumatic Stress Disorder in Two Independent Samples.” Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol. 39, no. 8, July 2014, pp. 1872–79. PubMed, https://doi.org/10.1038/npp.2014.34.
Vasireddy, Rani Priyanka, et al. “New Generation VMAT2 Inhibitors Induced Parkinsonism.” Clinical Parkinsonism & Related Disorders, vol. 3, Nov. 2020, p. 100078. PubMed Central, https://doi.org/10.1016/j.prdoa.2020.100078.
Wu, Qiuzi, et al. “Retrograde Trafficking of VMAT2 and Its Role in Protein Stability in Non-Neuronal Cells.” Journal of Biomedical Research, vol. 30, no. 6, Nov. 2016, pp. 502–09. PubMed Central, https://doi.org/10.7555/JBR.30.20160061.
Xiong, Nian, et al. “hVMAT2: A Target of Individualized Medication for Parkinson’s Disease.” Neurotherapeutics, vol. 13, no. 3, July 2016, pp. 623–34. Springer Link, https://doi.org/10.1007/s13311-016-0435-5.
Zhang, X., et al. “Puerarin Protects Dopaminergic Neurons in Parkinson’s Disease Models.” Neuroscience, vol. 280, Nov. 2014, pp. 88–98. ScienceDirect, https://doi.org/10.1016/j.neuroscience.2014.08.052.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.